Tevogen Bio Holdings Inc. (TVGN) announced new developments in its cytotoxic T lymphocyte or CTL therapy targeting Epstein-Barr virus or EBV-associated lymphomas, supported by AI-powered peptide selection technology.
The investigational therapy uses precision-engineered CTLs manufactured with Tevogen's proprietary ExacTcell platform, designed for high specificity and scalability.
As part of preclinical efforts, Tevogen's R&D team is conducting computer-based selection of EBV peptides to identify immunologically active viral targets.
These targets are undergoing laboratory confirmation to validate their ability to trigger robust CTL responses.
The work is being conducted in collaboration with Tevogen.AI, the company's artificial intelligence initiative, which is optimizing epitope selection across the EBV genome.
According to Chief Scientific Officer Neal Flomenberg, the therapy aims to directly target EBV proteins that drive cancer development through disruption of cellular pathways and malignant transformation.
No safety or efficacy data have yet been reported, as the program remains in the preclinical evaluation phase. A potential clinical trial is in preparation.
Tevogen plans to provide further updates as the EBV-specific CTL program progresses toward human studies. The company views EBV-driven cancers as a promising frontier for immunotherapy.
ExacTcell-enabled therapies are designed to deliver off-the-shelf T cell products with rapid, scalable manufacturing and potentially broad accessibility.
The EBV CTL program reflects Tevogen's broader strategy of combining precision immunotherapy with advanced computational tools to accelerate oncology drug development.
Currently, TVGN is trading at $1.21, down by 0.82 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.